Status:

COMPLETED

Accelerated Partial Breast Irradiation for Early Breast Cancer

Lead Sponsor:

Trans Tasman Radiation Oncology Group

Collaborating Sponsors:

Peter MacCallum Cancer Centre, Australia

Conditions:

Breast Cancer

Eligibility:

FEMALE

50+ years

Phase:

NA

Brief Summary

Hypothesis: In selected women with node-negative invasive breast cancer treated with breast conserving surgery, postoperative accelerated partial breast irradiation (APBI) limited to the region of th...

Detailed Description

This is a TROG multicentre feasibility study of APBI using 3D CRT in selected women with node-negative breast cancer treated by breast conserving surgery with negative margins. This is a one-arm feas...

Eligibility Criteria

Inclusion

  • Patients must fulfill all of the following criteria for admission to study:
  • Women aged \>= 50 years.
  • Histologically confirmed diagnosis of invasive breast carcinoma of non-lobular histology.
  • Bilateral mammograms performed within 6 months prior to registration.
  • Treated with breast conserving surgery (primary excision or re-excision) with negative radial resection margins of \>= 2 mm\* for both the invasive and if present, associated intraductal tumour.
  • \*Patients with superficial or deep resection margin of \< 2 mm are eligible if surgery has removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia.
  • Unifocal tumour measuring ≤ 20 mm in maximum microscopic dimension.
  • Negative nodal status determined by sentinel node biopsy, axillary dissection, or for women \> 70 years of age, clinical examination.
  • No evidence of distant metastasis.
  • Assessed by surgeon and radiation oncologist to be suitable for breast conserving therapy.
  • Ability to tolerate protocol therapy.
  • Protocol therapy must commence no later than 12 weeks from the last surgical procedure or 8 weeks from the last dose of chemotherapy.
  • Availability for long-term follow-up.
  • Women of child-bearing potential must use adequate contraception during RT.
  • Written informed consent.

Exclusion

  • Patients who fulfill any of the following criteria are not eligible for admission to study:
  • Multifocal or multicentric tumours.
  • Clinical or pathologic evidence of any of the following tumour features: extension to chest wall (excluding pectoralis muscle); oedema (including peau d'orange) or ulceration of skin; satellite skin nodules confined to the same breast; and inflammatory carcinoma.
  • Presence of extensive intraductal component (ductal carcinoma in situ occupying \> 25% of the primary invasive tumour and present adjacent to the primary tumour).
  • Node-positive breast cancer determined by sentinel node biopsy, axillary dissection, or in women \> 70 years of age, clinical examination.
  • Inability to localise surgical cavity on CT scans with no evidence of a surgical cavity, seroma or surgical clips delineating the tumour bed.
  • Treatment target volume estimated to occupy \> 25% of the ipsilateral whole breast volume.
  • Synchronous or metachronous bilateral invasive or intraductal breast cancer.
  • Locally recurrent breast cancer.
  • Ipsilateral breast implant.
  • Serious non-malignant disease that precludes definitive surgical or radiation treatment (e.g. scleroderma, systemic lupus erythematosus, cardiovascular/pulmonary/renal disease).
  • Previous or concomitant malignancies except non-melanoma skin cancer, carcinoma in situ of the cervix, and invasive carcinoma of the colon, thyroid, cervix, or endometrium treated five years prior to study entry.
  • Women who are pregnant or lactating.
  • Psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol

Key Trial Info

Start Date :

August 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 20 2018

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT00418210

Start Date

August 1 2007

End Date

August 20 2018

Last Update

December 5 2019

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Calvary Mater Newcastle

Newcastle, New South Wales, Australia, 2298

2

Royal North Shore Hospital

Sydney, New South Wales, Australia, 2069

3

Princess Alexandra Hospital

Wooloongabba, Queensland, Australia, 4102

4

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 8006